Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by toinv261on Mar 28, 2014 6:55pm
194 Views
Post# 22384324

RE:RE:WHAT DID THE CC PERSON ACTUALLY SAY TO THE PRESS?

RE:RE:WHAT DID THE CC PERSON ACTUALLY SAY TO THE PRESS?Jkj, thanks as always. Let's hope it's addressed. There seems to be so many positive aspects to this compound...benefits to many health aspects beyond plaque reduction. 

For example a posting from Biotech777..."Also keep in mind that plaque is a broad term. There are various types of plaque within the artery wall ranging from soft lipid plaques to fibro calcific plaques to fully calcified. RVX-208 only has an effect on soft lipid base plaques."

The following paragraph. "The good news is that the percentage of (plaque) reduction is less important. This type of therapy is not about improving blood flow, but rather reducing risk for heart attack. We know that most (apptox 70%) of heart attacks are caused by ruptured plaque. The type of plaque that is most likely to rupture is just happens to be soft lipid based plaque. This is why even with very low regression numbers, there can be improvements in clinical outcomes such as reductions in heart attacks. Soft lipid based plaques form pools called liid rich necrotic cores. Nearby certain scavenger cells express inflammatory compounds that destabilze the area. So reducing lipid content adjacent to these pools is important to stabilizing the lesion and reducing the chance of a heart attack".

So it looks like 208 and it's MACE results are supported by the biochemistry. Hope I understood this properly.

Toinv
Bullboard Posts